• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24069 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia, first line) - Benefit assessment according to §35a Social Code Book V]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [X-rays of the lower back in the 20 to 49 age patient group referred from primary section]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2009     Committee for New Health Technology Assessment (CNHTA) [WT1 gene mRNA, quantitative[real-time RT-PCR]]
2011     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Wound treatment in the patient's own home by collaboration between hospital and home care: a health technology assessment]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Wound team - organization of treatment to patients with problem wounds]
2014     The HTA Center of the Stockholm County Council/Gotland [Wound infections after surgery-effect of triclosan-coated sutures]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole-exome sequencing in patients with neurological disorders]
2009     Committee for New Health Technology Assessment (CNHTA) [Whole-body cryotherapy]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole exome sequencing in patients with undiagnosed neurological diseases]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole exome sequencing in patients with intellectual disability and/or autism spectrum disorder]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole exome sequencing in epileptic encephalopathies]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole exome sequencing for patients with intellectual disability/mental retardation or ASD]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [When outcome is a balance. Methods to measure combined utility in obstetrics. Ancillary study of Foetal growth retardation at term: induction of labour or not? A comparison of maternal and neonatal outcome, maternal quality of life and costs (DIGITAT). The Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT)]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Wheelchairs and wheelchair accessories]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [What type of evidence is currently being considered in the development of clinical practice guidelines for rare diseases? - rapid report]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [What is the (cost-) effectiveness of a multidisciplinary treatment program for patients with clinically manifest vascular disease or at high risk for atherosclerosis on risk factor reduction?]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Weighted blankets and vests: safety, efficacy and issues related to their use in different intervention settings]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Weight reduction in essential hypertension]
2027     Norwegian Medical Products Agency (NOMA) [Wearable cardioverter defibrillator (LifeVest) for people with high risk of sudden cardiac arrest: a single technology assessment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (hereditary transthyretin amyloidosis) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) - Addendum to Commission A22-114]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voxelotor (sickle cell disease) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Vosoritide in achondroplasia]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Vosoritide in achondroplasia]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia, ≥ 4 months) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia, ≥ 2 years) – Addendum to Project A23-92]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vortioxetine (Addendum to Commission A15-16)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vortioxetine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voretigene neparvovec (vision loss due to inherited retinal dystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voretigene neparvovec (inherited retinal dystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     National Evidence-based Healthcare Collaborating Agency (NECA) [von Willebrand Factor collagen binding activity [high quality immunoassay]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Volumetric modulated arc therapy in patients with lung cancer, prostate cancer, high-risk gliomas and tumors in head and neck]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Volume of operations and the quality of outcome for PTCA]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Volume of operations and the quality of outcome for elective surgery of an abdominal aortic aneurysm]
2025     Norwegian Medical Products Agency (NOMA) [Volatile gas capture technology. Summary of a health technology assessment by Scottish Health Technologies Group: health technology assessment without submitted documentation]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Volanesorsen (familial chylomicronaemia syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voclosporin (lupus nephritis) - Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [VKORCI genotyping[Real-time PCR-melting point analysis]]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Vivostat® fibrin sealant]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Vitamin D screening in adults]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Vitamin D - population screening and supplementation in populations with deficit]
2006     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Visual mobility aids for patients with night blindness]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vismodegib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vismodegib - Benefit assessment according §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vismodegib - addendum to commission A16-09]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Vision screening of preschool children]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Virtual hysterosalpingograghy to evaluate the uterus and tubes patency]
2010     Haute Autorite de sante (HAS) [Virtual colonoscopy: meta-analysis of diagnostic accuracy, indications and conditions of use]
2008     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Virtual colonoscopy for colorectal cancer]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Virtual colonoscopy for colorectal cancer screening in patients with diverticular disease]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vildagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vildagliptin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vildagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2008     Belgian Health Care Knowledge Centre (KCE) [Video registration of endoscopic surgery: a rapid assessment]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Video head impulse test in vertigo]
2009     Committee for New Health Technology Assessment (CNHTA) [VHL exon deletion/duplication test[MLPA]]
2008     Committee for New Health Technology Assessment (CNHTA) [VHL exon deletion/duplication test[MLPA]]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vestronidase alfa (mucopolysaccharidosis type VII) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Vertebroplasty or kyphoplasty in osteoporotic vertebral fractures]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vericiguat (cardiac failure) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vericiguat (cardiac failure) - Addendum to Commission A21-120]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Ventricular assist devices for heart failure]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Ventricular assist devices for heart failure]
2011     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Ventilation systems in operating rooms a health technology assessment]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Venetoclax for relapsed or refractory chronic lymphocytic leukemia]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia): Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Addendum to Commission A20-39]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia; combination with rituximab) - Addendum to Commission A18-81]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V - Addendum]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Vemurafenib in combination with Cobimetinib for advanced melanoma]
2016     Institute for Clinical Effectiveness and Health Policy (IECS) [Vemurafenib for the treatment of pediatric patients with braf v600e mutation-positive ganglioglioma]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Velmanase alfa (enzyme replacement treatment for mild to moderate alpha-mannosidosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vedolizumab (antibiotic refractory chronic pouchitis) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vedolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula. Update]
2011     Canary Health Service [Variations, inequalities, degree of inappropriate use and avoidable costs of imaging tests in the diagnosis and follow-up of stroke patients in the Canary Islands]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Variability in medical practice]
2025     HTA South [Vaporization with green laser for benign prostatic hyperplasia: a systematic review and assessment of medical, economic, ethical and organisational aspects]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vandetanib (second assessment) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) - Benefit assessment according to § 35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vandetanib (medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vandetanib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Vancomycin trough for therapeutic monitoring]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vamorolone (Duchenne muscular dystrophy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2003     The Netherlands Organisation for Health Research and Development (ZonMw) [Valuing informal care in health technology assessment (HTA)]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Valuation of EQ-5D-5L health states in Korea]